empagliflozin; linagliptin
EMPAGLIFLOZIN; LINAGLIPTIN (empagliflozin; linagliptin) is contains: empagliflozin, a sglt2 inhibitor, linagliptin, a dpp-4 inhibitor, and metformin hcl, a biguanide. Approved for cardiovascular (cv) death in adults with type 2 diabetes mellitus, established cv disease [see ], established cv disease and 2 more indications.
Drug data last refreshed 14h ago
contains: empagliflozin, a SGLT2 inhibitor, linagliptin, a DPP-4 inhibitor, and metformin HCl, a biguanide. Empagliflozin Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting…
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.